Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial

S. C. Crawford; P. A. Vasey; J. Paul; A. Hay; J. A. Davis; S. B. Kaye

doi:10.1200/jco.2005.23.16_suppl.5003

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.5003 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5003-5003 ◽

Cited By ~ 1

Author(s):

S. C. Crawford ◽

P. A. Vasey ◽

J. Paul ◽

A. Hay ◽

J. A. Davis ◽

...

Keyword(s):

Ovarian Cancer ◽

International Comparison ◽

Advanced Ovarian Cancer

Get full-text (via PubEx)

Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70316-6 ◽

2007 ◽

Vol 2007 ◽

pp. 66-67

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

International Comparison ◽

Advanced Ovarian Cancer

Get full-text (via PubEx)

Does Aggressive Surgery Only Benefit Patients with Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial

Yearbook of Obstetrics Gynecology and Women s Health ◽

10.1016/s1090-798x(08)70286-8 ◽

2007 ◽

Vol 2007 ◽

pp. 413-415

Author(s):

R.L. Coleman

Keyword(s):

Ovarian Cancer ◽

International Comparison ◽

Advanced Ovarian Cancer

Get full-text (via PubEx)

Experimental Drug Shows Activity Against Advanced Ovarian Cancer in Phase II Trial

Ob Gyn News ◽

10.1016/s0029-7437(07)70576-1 ◽

2007 ◽

Vol 42 (13) ◽

pp. 2

Author(s):

PATRICE WENDLING

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Experimental Drug

Get full-text (via PubEx)

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour I'Etude des Cancers Ovariens

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70319-1 ◽

2007 ◽

Vol 2007 ◽

pp. 69-70

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Study Group ◽

Line Treatment ◽

First Line ◽

Cancer Study ◽

Cancer Study Group ◽

Intergroup Trial ◽

First Line Treatment

Get full-text (via PubEx)

8. Internationales Symposium Advanced Ovarian Cancer update: Das richtige Target definieren und gezieltere Kombinationstherapien

Onkologische Welt ◽

10.1055/s-0038-1631239 ◽

2011 ◽

Vol 02 (03) ◽

pp. 105-106

Author(s):

Bettina Reich

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer

Seit 1996 ist das zweijährliche Weiterbildungsmeeting der spanischen Ovarialkarzinomgruppe eine Institution. Nunmehr wird es in Kooperation mit der ESMO durchgeführt, um insgesamt mehr Onkologen aus Europa zu erreichen. Denn die Behandlung des rezidivierten Ovarialkarzinoms stellt nach wie vor eine große Herausforderung dar. Zudem das Ovarialkarzinom meist erst im fortgeschrittenen Stadium entdeckt wird. Erst in den vergangenen Jahren konnten die Therapieoptionen in diesem Bereich etwas verbessert werden. Immer mehr zielgerichtete Kombinationen werden eingesetzt. Trotzdem muss eine noch genauere Zieldefinition am Anfang stehen, um letztlich wirklich Erfolge zu erzielen.

Get full-text (via PubEx)

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

10.1055/s-0040-1717197 ◽

2020 ◽

Author(s):

A Schnelzer ◽

P Harter ◽

J Sehouli ◽

U Canzler ◽

F Marmé ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Newly Diagnosed ◽

Platinum Based Chemotherapy

Get full-text (via PubEx)

Efficacy and safety of niraparib in older patients with advanced ovarian cancer (OC): results from the PRIMA/ENGOT-OV26/GOG-3012 trial

10.1055/s-0040-1718222 ◽

2020 ◽

Author(s):

F Heitz ◽

G Valabrega ◽

B Pothuri ◽

A Oaknin ◽

W Graybill ◽

...

Keyword(s):

Ovarian Cancer ◽

Older Patients ◽

Advanced Ovarian Cancer ◽

Efficacy And Safety

Get full-text (via PubEx)

Chemoinducible Virotherapy for advanced ovarian cancer

Zentralblatt für Gynäkologie ◽

10.1055/s-2005-921017 ◽

2005 ◽

Vol 127 (04) ◽

Author(s):

I Herrmann ◽

M Porten ◽

A Menzel ◽

DT Curiel ◽

D Niederacher ◽

...

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer

Get full-text (via PubEx)

Laparoscopy vs. laparotomy for advanced ovarian cancer: a systematic review of the literature

Minerva Medica ◽

10.23736/s0026-4806.19.06132-9 ◽

2019 ◽

Vol 110 (4) ◽

Cited By ~ 1

Author(s):

Salvatore Gueli Alletti ◽

Vito A. Capozzi ◽

Andrea Rosati ◽

Ilaria De Blasis ◽

Stefano Cianci ◽

...

Keyword(s):

Systematic Review ◽

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Review Of The Literature

Get full-text (via PubEx)

BODY MASS INDEX AND BEVACIZUMAB IN FIRST LINE TREATMENT FOR ADVANCED OVARIAN CANCER (AOC)

10.26226/morressier.5770e29cd462b80290b4c076 ◽

2016 ◽

Author(s):

Ida Paris

Keyword(s):

Ovarian Cancer ◽

Body Mass Index ◽

Body Mass ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Get full-text (via PubEx)